| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/HEP.23286 |
| P8608 | Fatcat ID | release_y4a3becvrrajpmqedaivitgurq |
| P698 | PubMed publication ID | 19885875 |
| P5875 | ResearchGate publication ID | 38063908 |
| P50 | author | Lise L Gluud | Q52353956 |
| Aleksander Krag | Q56849497 | ||
| P2093 | author name string | Erik Christensen | |
| Kurt Christensen | |||
| P2860 | cites work | Terlipressin for hepatorenal syndrome | Q24243962 |
| Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study | Q24653790 | ||
| Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles | Q29618882 | ||
| The role of vasopressin in vasodilatory septic shock | Q33362358 | ||
| Assessment of regression-based methods to adjust for publication bias through a comprehensive simulation study | Q33399292 | ||
| Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study | Q33966802 | ||
| Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement | Q33993977 | ||
| Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. | Q34011626 | ||
| Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites | Q34062056 | ||
| Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club | Q34062215 | ||
| Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion | Q34065752 | ||
| Enhancement of renal function with ornipressin in a patient with decompensated cirrhosis | Q34528259 | ||
| Review article: pathogenesis and pathophysiology of hepatorenal syndrome--is there scope for prevention? | Q35873829 | ||
| Bias in clinical intervention research. | Q36380552 | ||
| A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome | Q37061659 | ||
| Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses? | Q43707230 | ||
| Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study | Q44080043 | ||
| Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial | Q44287768 | ||
| Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study | Q45003218 | ||
| An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response | Q46537222 | ||
| Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis | Q46827576 | ||
| Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. | Q46948629 | ||
| Blinded trials taken to the test: an analysis of randomized clinical trials that report tests for the success of blinding | Q51917104 | ||
| Quality of reporting of noninferiority and equivalence randomized trials | Q53000120 | ||
| Octreotide in the treatment of the hepatorenal syndrome in cirrhotic patients. | Q55068244 | ||
| Hepatorenal syndrome | Q56683659 | ||
| Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome | Q56925565 | ||
| Controlled trial of terlipressin ('Glypressin') versus vasopressin in the early treatment of oesophageal varices | Q72528478 | ||
| The hepatorenal syndrome | Q74618980 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | systematic review | Q1504425 |
| P304 | page(s) | 576-584 | |
| P577 | publication date | 2010-02-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome | |
| P478 | volume | 51 |
| Q86377764 | A Treat-to-Target Concept to Guide the Medical Management of Hepatorenal Syndrome |
| Q34873261 | A pilot study to evaluate renal hemodynamics in cirrhosis by simultaneous glomerular filtration rate, renal plasma flow, renal resistive indices and biomarkers measurements |
| Q61361815 | Acute kidney injury |
| Q38243669 | Acute kidney injury and hepatorenal syndrome in cirrhosis. |
| Q41226181 | Acute kidney injury in hepatitis B-related acute-on-chronic liver failure without preexisting liver cirrhosis |
| Q55097285 | Acute-on-Chronic Liver Failure. |
| Q50956831 | Acute-on-chronic liver failure |
| Q37839621 | Acute-on-chronic liver failure: the kidneys |
| Q35852815 | Albumin treatment regimen for type 1 hepatorenal syndrome: a dose-response meta-analysis |
| Q38098443 | Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II). |
| Q33805260 | Bile Cast Nephropathy in Patients with Acute Kidney Injury Due to Hepatorenal Syndrome: A Postmortem Kidney Biopsy Study |
| Q37922959 | Care of Chronic Liver Disease |
| Q33594931 | Cirrhosis and its complications: evidence based treatment |
| Q38110291 | Cirrhotic ascites review: Pathophysiology, diagnosis and management |
| Q37429032 | Clinical course and prognostic factors of hepatorenal syndrome: A retrospective single-center cohort study |
| Q36345210 | Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis |
| Q38679099 | Comparative efficacy of vasoconstrictor therapies for type 1 hepatorenal syndrome: a network meta-analysis |
| Q38424360 | Complications of cirrhosis. A 50 years flashback. |
| Q37045780 | Cross-Sectional Guidelines for Therapy with Blood Components and Plasma Derivatives: Chapter 5 Human Albumin - Revised |
| Q33811643 | Current concepts in the diagnosis and classification of renal dysfunction in cirrhosis |
| Q38002958 | Current limits and future challenges in the management of renal dysfunction in patients with cirrhosis: report from the International Club of Ascites |
| Q41059672 | Current position of vasoconstrictor and albumin infusion for type 1 hepatorenal syndrome |
| Q93140630 | Current treatment strategies for hepatorenal syndrome |
| Q38052261 | Cystic Fibrosis: Management of Haemoptysis |
| Q38779628 | Diuretic usage for protection against end-organ damage in liver cirrhosis and heart failure. |
| Q34247676 | Effect of various drugs used in conservative therapy of hepatorenal syndrome: a retrospective drug utilization study |
| Q85364971 | Effects of terlipressin on pulmonary artery pressure in a septic cooled infant: an echocardiographic assessment |
| Q38858262 | Emerging hepatic syndromes: pathophysiology, diagnosis and treatment. |
| Q89792767 | Endothelin-1/Nitric Oxide Ratio as a Predictive Factor of Response to Therapy With Terlipressin and Albumin in Patients With Type-1 Hepatorenal Syndrome |
| Q41156370 | Evaluation of acute kidney injury and its response to terlipressin in patients with acute-on-chronic liver failure |
| Q35891577 | From the nephrologist's point of view: diversity of causes and clinical features of acute kidney injury |
| Q91741801 | Functional magnetic resonance imaging-based assessment of terlipressin vs. octreotide on renal function in cirrhotic patients with acute variceal bleeding (CHESS1903): study protocol of a multicenter randomized controlled trial |
| Q86895930 | Hepatobiliary quiz-8 (2013) |
| Q91828497 | Hepatorenal Syndrome Type 1: Current Challenges And Future Prospects |
| Q37920945 | Hepatorenal Syndrome in the Intensive Care Unit |
| Q38654403 | Hepatorenal Syndrome: A Review of Pathophysiology and Current Treatment Options |
| Q87420636 | Hepatorenal syndrome |
| Q95597399 | Hepatorenal syndrome |
| Q38850006 | Hepatorenal syndrome in cirrhosis: diagnostic, pathophysiological, and therapeutic aspects |
| Q84965903 | Hepatorenal syndrome, pharmacological therapy, and liver transplantation |
| Q87061810 | Hepatorenal syndrome: The last pieces of the puzzle or not yet? |
| Q26777608 | Hepatorenal syndrome: Update on diagnosis and treatment |
| Q87088748 | Hepatorenal syndrome: focus |
| Q36093575 | Hepatorenal syndrome: the 8th international consensus conference of the Acute Dialysis Quality Initiative (ADQI) Group |
| Q26852608 | Human albumin in the management of complications of liver cirrhosis |
| Q36812531 | Hyponatremia and Hepatorenal Syndrome |
| Q37141412 | Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1* |
| Q38455292 | Impact of molecular adsorbent recirculating system on renal recovery in type-1 hepatorenal syndrome patients with chronic liver failure |
| Q36090423 | Improving survival in decompensated cirrhosis |
| Q49753643 | Induction of renal artery hyperresponsiveness by alpha1-adrenoceptor in hepatorenal syndrome |
| Q86283845 | Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012 |
| Q38199770 | Kidney injury in cirrhosis: pathophysiological and therapeutic aspects of hepatorenal syndromes |
| Q43209206 | Kidneys in chronic liver diseases |
| Q58097604 | Komplikationen der Leberzirrhose |
| Q56986478 | Long-term treatment of hepatorenal syndrome as a bridge to liver transplantation |
| Q38569513 | Management of Renal Failure and Ascites in Patients with Cirrhosis |
| Q40706978 | Management of acute kidney injury in cirrhosis |
| Q34475601 | Management of cirrhotic ascites |
| Q37932341 | Management of end-stage liver disease in HIV/hepatitis C virus co-infection |
| Q38463841 | Management of hepatorenal syndrome |
| Q37913980 | Management of hepatorenal syndrome in patients with cirrhosis. |
| Q26773222 | Modulation of splanchnic circulation: Role in perioperative management of liver transplant patients |
| Q47807120 | New Developments in Hepatorenal Syndrome |
| Q35565646 | New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection |
| Q36422621 | Noradrenalin versus the combination of midodrine and octreotide in patients with hepatorenal syndrome: randomized clinical trial. |
| Q57073583 | Noradrenaline for reverting hepatorenal syndrome: a prospective, observational, single-center study |
| Q51059723 | Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study |
| Q38173738 | Optimal management of hepatorenal syndrome in patients with cirrhosis. |
| Q41879676 | Predictors of health-related quality of life in outpatients with cirrhosis: results from a prospective cohort. |
| Q34816170 | Predictors of renal recovery in patients with pre-orthotopic liver transplant (OLT) renal dysfunction |
| Q37058079 | Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics |
| Q30251763 | Protecting the Kidney in Liver Transplant Candidates: Practice-Based Recommendations From the American Society of Transplantation Liver and Intestine Community of Practice |
| Q38012022 | Recent advances in our understanding of hepatorenal syndrome |
| Q34047665 | Renal dysfunction in patients with cirrhosis: Where do we stand? |
| Q37951325 | Renal failure in chronic liver disease and the hepatorenal syndrome |
| Q26785971 | Renal failure in cirrhosis: Emerging concepts |
| Q26770382 | Response to the NCEPOD report: development of a care bundle for patients admitted with decompensated cirrhosis—the first 24 h |
| Q33698303 | Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies. |
| Q38060261 | Review article: towards a considered and ethical approach to organ support in critically‐ill patients with cirrhosis |
| Q39387113 | Role of albumin in cirrhosis: from a hospitalist's perspective. |
| Q35574320 | Role of human albumin in the management of complications of liver cirrhosis |
| Q41842297 | Severe ischemic bowel necrosis caused by terlipressin during treatment of hepatorenal syndrome. |
| Q39304075 | Survival benefits of terlipressin and non-responder state in hepatorenal syndrome: A meta-analysis |
| Q39681613 | TERLIPRESSIN VERSUS NORADRENALINE FOR HEPATORENAL SYNDROME. Economic evaluation under the perspective of the Brazilian Public Health System |
| Q42379057 | Terlipressin and hepatorenal syndrome: what is important for nephrologists and hepatologists |
| Q45795579 | Terlipressin and hyponatraemia: the cause or the treatment? |
| Q24200336 | Terlipressin for hepatorenal syndrome |
| Q37825655 | Terlipressin in hepatorenal syndrome: Evidence for present indications |
| Q55112410 | Terlipressin in the treatment of hepatorenal syndrome: A systematic review and meta-analysis. |
| Q60198884 | Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial |
| Q47737114 | Terlipressin versus other vasoactive drugs for hepatorenal syndrome. |
| Q57689645 | Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome |
| Q84514522 | Terlipressin: an asset for hepatologists! |
| Q36133714 | The Effect of Renal Function Impairment on the Mortality of Cirrhotic Patients: A Nationwide Population-Based 3-Year Follow-up Study |
| Q34314452 | The Meaning of Acute Kidney Injury and Its Relevance to Intensive Care and Anaesthesia |
| Q27009164 | The conservative and interventional treatment of the complications of liver cirrhosis: Part 2 of a series on liver cirrhosis |
| Q37315198 | The effect of octreotide on urine output during orthotopic liver transplantation and early postoperative renal function; a randomized, double-blind, placebo-controlled trial |
| Q61448028 | The effects of terlipressin and direct portacaval shunting on liver hemodynamics following 80% hepatectomy in the pig |
| Q82462480 | The use of terlipressin in cirrhotic patients with refractory ascites and normal renal function: A multicentric study |
| Q36769062 | Therapeutic potential of targeting the renin angiotensin system in portal hypertension. |
| Q35654104 | Therapeutic response to vasoconstrictors in hepatorenal syndrome parallels increase in mean arterial pressure: a pooled analysis of clinical trials. |
| Q24198269 | Transjugular intrahepatic portosystemic shunts for hepatorenal syndrome |
| Q27000268 | Treatment and management of ascites and hepatorenal syndrome: an update |
| Q26799273 | Understanding the Complexities of Cirrhosis |
| Q38735909 | Where does the Albumin go? Human Albumin Solution usage following the implementation of a demand management programme |
| Q87081951 | [Hepatorenal syndrome] |
Search more.